68 related articles for article (PubMed ID: 28126725)
1. Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
Degnim AC; Hoskin TL; Arshad M; Frost MH; Winham SJ; Brahmbhatt RA; Pena A; Carter JM; Stallings-Mann ML; Murphy LM; Miller EE; Denison LA; Vachon CM; Knutson KL; Radisky DC; Visscher DW
Clin Cancer Res; 2017 Jul; 23(14):3945-3952. PubMed ID: 28126725
[No Abstract] [Full Text] [Related]
2. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.
Goff SL; Danforth DN
Clin Breast Cancer; 2021 Feb; 21(1):e63-e73. PubMed ID: 32893093
[TBL] [Abstract][Full Text] [Related]
3. Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues.
Degnim AC; Visscher DW; Hoskin TL; Frost MH; Vierkant RA; Vachon CM; Shane Pankratz V; Radisky DC; Hartmann LC
Breast Cancer Res Treat; 2012 May; 133(1):169-77. PubMed ID: 21881938
[TBL] [Abstract][Full Text] [Related]
4. Location of tumor affects local and distant immune cell type and number.
Hensel JA; Khattar V; Ashton R; Lee C; Siegal GP; Ponnazhagan S
Immun Inflamm Dis; 2017 Mar; 5(1):85-94. PubMed ID: 28250928
[TBL] [Abstract][Full Text] [Related]
5. Repolarizing macrophages improves breast cancer therapy.
Cassetta L; Pollard JW
Cell Res; 2017 Aug; 27(8):963-964. PubMed ID: 28429765
[TBL] [Abstract][Full Text] [Related]
6. A Computational Modeling Approach for Deriving Biomarkers to Predict Cancer Risk in Premalignant Disease.
Dhawan A; Graham TA; Fletcher AG
Cancer Prev Res (Phila); 2016 Apr; 9(4):283-95. PubMed ID: 26851234
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab and Other CD20
Gelfand JM; Cree BAC; Hauser SL
Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
[TBL] [Abstract][Full Text] [Related]
8. CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.
Kerekes D; Visscher DW; Hoskin TL; Radisky DC; Brahmbhatt RD; Pena A; Frost MH; Arshad M; Stallings-Mann M; Winham SJ; Murphy L; Denison L; Carter JM; Knutson KL; Degnim AC
Breast Cancer Res Treat; 2018 Feb; 167(3):649-658. PubMed ID: 29090365
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review on the applications of ferrite nanoparticles in the diagnosis and treatment of breast cancer.
Akhtar MF; Afzaal A; Saleem A; Roheel A; Khan MI; Imran M
Med Oncol; 2024 Jan; 41(2):53. PubMed ID: 38198041
[TBL] [Abstract][Full Text] [Related]
11. The current advances of lncRNAs in breast cancer immunobiology research.
Fonseca-Montaño MA; Vázquez-Santillán KI; Hidalgo-Miranda A
Front Immunol; 2023; 14():1194300. PubMed ID: 37342324
[TBL] [Abstract][Full Text] [Related]
12. Inflammation, Infiltration, and Evasion-Tumor Promotion in the Aging Breast.
Cruz-Reyes N; Radisky DC
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980723
[TBL] [Abstract][Full Text] [Related]
13. Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort.
Sherman ME; Vierkant RA; Masters M; Radisky DC; Winham SJ; Degnim AC; Vachon CM; Patel AV; Teras LR
Cancer Prev Res (Phila); 2023 Mar; 16(3):175-184. PubMed ID: 36596665
[TBL] [Abstract][Full Text] [Related]
14. Impact of intestinal dysbiosis on breast cancer metastasis and progression.
Zhang J; Xie Q; Huo X; Liu Z; Da M; Yuan M; Zhao Y; Shen G
Front Oncol; 2022; 12():1037831. PubMed ID: 36419880
[TBL] [Abstract][Full Text] [Related]
15. Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
Ogony J; Hoskin TL; Stallings-Mann M; Winham S; Brahmbhatt R; Arshad MA; Kannan N; Peña A; Allers T; Brown A; Sherman ME; Visscher DW; Knutson KL; Radisky DC; Degnim AC
Breast Cancer Res Treat; 2023 Jan; 197(2):277-285. PubMed ID: 36380012
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia.
Gan CP; Lee BKB; Lau SH; Kallarakkal TG; Zaini ZM; Lye BKW; Zain RB; Sathasivam HP; Yeong JPS; Savelyeva N; Thomas G; Ottensmeier CH; Ariffin H; Cheong SC; Lim KP
Front Immunol; 2022; 13():954567. PubMed ID: 36119104
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors.
Feng TY; Azar FN; Dreger SA; Rosean CB; McGinty MT; Putelo AM; Kolli SH; Carey MA; Greenfield S; Fowler WJ; Robinson SD; Rutkowski MR
Cancer Immunol Res; 2022 Nov; 10(11):1309-1325. PubMed ID: 36040846
[TBL] [Abstract][Full Text] [Related]
18. Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.
Lin S; Zheng Y; Wang M; Zhou L; Zhu Y; Deng Y; Wu Y; Zhang D; Li N; Kang H; Dai Z
Mol Biol Rep; 2022 Mar; 49(3):2255-2263. PubMed ID: 35079936
[TBL] [Abstract][Full Text] [Related]
19. Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning.
de Bel T; Litjens G; Ogony J; Stallings-Mann M; Carter JM; Hilton T; Radisky DC; Vierkant RA; Broderick B; Hoskin TL; Winham SJ; Frost MH; Visscher DW; Allers T; Degnim AC; Sherman ME; van der Laak JAWM
NPJ Breast Cancer; 2022 Jan; 8(1):13. PubMed ID: 35046392
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
